• The median time to achieve the target BP (systolic blood pressure ≤160 mmHg to ≥140 mmHg) within 30 minutes of the initiation of clevidipine infusion. [ Time Frame: Within 30 minutes of the initiation of study drug infusion ] [ Designated as safety issue: No ]
  

• The percentage of patients who reach a systolic blood pressure of ≤160 mmHg within 30 minutes of the initiation of clevidipine infusion [ Time Frame: Within 30 minutes of the initiation of study drug infusion ] [ Designated as safety issue: No ]
  
• Percent change from baseline in systolic blood pressure during the initial 30 minutes of clevidipine infusion [ Time Frame: During the initial 30 minutes of study drug infusion ] [ Designated as safety issue: No ]
  
• Magnitude, frequency and duration of systolic blood pressure excursions (calculated as area under the curve) outside the target range normalized per hour for the duration of the clevidipine monotherapy infusion [ Time Frame: Duration of the study drug infusion (up to 96 hours) ] [ Designated as safety issue: No ]
  
• Percent time blood pressures were maintained within the target range (systolic blood pressure ≤160 mmHg to ≥140 mmHg) over each 24 hours during monotherapy infusion of clevidipine [ Time Frame: Every 24 hours (for up to 96 hours) ] [ Designated as safety issue: No ]
  
• Mean and median dose of clevidipine during the treatment period [ Time Frame: Up to 96 hours ] [ Designated as safety issue: No ]
  
• Proportion of patients requiring the addition of an alternative antihypertensive agent(s) with or without clevidipine [ Time Frame: Up to 96 hours ] [ Designated as safety issue: No ]
  
• Percent change in heart rate during the initial 30 minutes of clevidipine infusion [ Time Frame: During initial 30 minutes of study drug infusion ] [ Designated as safety issue: Yes ]
  
• The percentage of patients whose systolic blood pressure is less than <90 mmHg within 30 minutes of the initiation of clevidipine infusion [ Time Frame: Within 30 minutes of the initiation of study drug infusion ] [ Designated as safety issue: Yes ]
  
• Safety of a prolonged infusion of clevidipine (up to 96 hours) [ Time Frame: Up to 7 days following termination of study drug infusion ] [ Designated as safety issue: Yes ]
  

This is a multicenter, single-arm, non-blinded dose titration efficacy and safety trial evaluating the ability of clevidipine, a vascular-selective L-type calcium channel antagonist, to rapidly control acute hypertension in patients with intracerebral hemorrhage. Informed consent will be obtained from patients meeting the inclusion criteria before the initiation of any study-specific procedures. At screening a clinical and neurological examination will be carried out. For the purposes of this study, acute hypertension will be defined as SBP >160 mmHg immediately prior to initiation of study drug. Patients with and an intracerebral hemorrhage (ICH) volume ≤60 cc as well those with an ICH volume >60 cc will be enrolled. Infusion of study drug will be initiated within 6 hours of ICH symptom onset. All eligible patients will be enrolled to receive clevidipine in an open label manner. Clevidipine will be infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates can be attempted as needed to obtain the target SBP range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect is to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) is attained. Clevidipine infusion may continue for up to a maximum of 96 hours. Twenty-four hour follow-up CT scan results will be recorded, including measurement of intracerebral and intraventricular hematoma volumes and measurement of perihematoma edema volume. Assessment of safety will be performed throughout the treatment period and until 6 hours after termination of study drug. Patients will be followed for 7 days following termination of the clevidipine infusion.